Research frontier of inflammatory bowel disease

doi:10.3785/j.issn.1008-9292.2019.06.15

J Zhejiang Univ (Med Sci)

2019, Vol. 48

Issue (3): 334-341 DOI: 10.3785/j.issn.1008-9292.2019.06.15

Research frontier of inflammatory bowel disease

FAN Yihong(

),LYU Bin*(

)

Department of Gastroenterology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Key Laboratory for Pathophysiological Research on Digestive System Diseases of Zhejiang Province, Hangzhou 310006, China

Download:

HTML( 12 )

PDF(958KB)
Export: BibTeX | EndNote (RIS)

Key words： Inflammatory bowel diseases/epidemiology Inflammatory bowel diseases/physiopathology Inflammatory bowel diseases/diagnosis Inflammatory bowel diseases/therapy Congresses

Received: 30 May 2019 Published: 04 September 2019

CLC:

R574.5

Corresponding Authors: LYU Bin E-mail: yhfansjr@163.com;lvbin@medmail.com.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Yihong
	LYU Bin

Cite this article:

FAN Yihong, LYU Bin. Research frontier of inflammatory bowel disease. J Zhejiang Univ (Med Sci), 2019, 48(3): 334-341.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2019.06.15 OR http://www.zjujournals.com/med/Y2019/V48/I3/334

Fig 1 Essential molecular players in the multistep adhesion cascade

Tab 1 Toronto inflammatory bowel diseases global endoscopic reporting (TIGER) score^[15]

Fig 2 Mammalian integrin αβ heterodimers pairing


[1]	LICHTENSTEIN G R , LOFTUS E V , ISAACS K L et al. ACG clinical guideline:management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113 (4): 481- 517 doi: 10.1038/ajg.2018.27

[2]	COSTA J , MAGRO F , CALDEIRA D et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2013, 19 (10): 2098- 2110 doi: 10.1097/MIB.0b013e31829936c2

[3]	NGUYEN G C , CHONG C A , CHONG R Y . National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States[J]. J Crohns Colitis, 2014, 8 (4): 288- 295 doi: 10.1016/j.crohns.2013.09.001

[4]	XU F , LIU Y , WHEATON A G et al. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States[J]. Appl Health Econ Health Policy, 2019, 17 (1): 77- 91 doi: 10.1007/s40258-018-0432-4

[5]	MALARCHER C A , WHEATON A G , LIU Y et al. Hospitalizations for Crohn's disease-United States, 2003-2013[J]. MMWR Morb Mortal Wkly Rep, 2017, 66 (14): 377- 381 doi: 10.15585/mmwr.mm6614a1

[6]	LIU J Z , VAN SOMMEREN S , HUANG H et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47 (9): 979- 986 doi: 10.1038/ng.3359

[7]	BUHM H , AKIYAMA MASATO A , KYUNG-KON K et al. Amino acid position 37 of HLA-DRβ1 affects susceptibility to Crohn's disease in Asians[J]. Hum Mol Genet, 2018, 27 (22): 3901- 3910 doi: 10.1093/hmg/ddy285

[8]	HONG M , YE B D , YANG S K et al. Immunochip meta-analysis of inflammatory bowel disease identifies three novel loci and four novel associations in previously reported loci[J]. J Crohns Colitis, 2018, 12 (6): 730- 741 doi: 10.1093/ecco-jcc/jjy002

[9]	CLEYNEN I , BOUCHER G , JOSTINS L et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes:a genetic association study[J]. Lancet, 2016, 387 (10014): 156- 167 doi: 10.1016/S0140-6736(15)00465-1

[10]	PALMELA C , CHEVARIN C , XU Z et al. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Gut, 2018, 67 (3): 574- 587 doi: 10.1136/gutjnl-2017-314903

[11]	IMAI J , KITAMOTO S , SUGIHARA K et al. Adherent-invasive Escherichia coli colonization promotes intestinal fibrosis via activation of IL-33/ST2 signaling[J]. Mucosal Immunol, 2019, 12 (3): 632- 643 doi: 10.1038/s41385-019-0138-4

[12]	PANéS J , SALAS A . Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease[J]. J Crohns Colitis, 2018, 12 (suppl_2): S633- S640 doi: 10.1093/ecco-jcc/jjy011

[13]	LOBATóN T , VERMEIRE S , VAN ASSCHE G et al. Review article:anti-adhesion therapies for inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2014, 39 (6): 579- 594 doi: 10.1111/apt.12639

[14]	MACKAY C R , MACKAY I R , ROSENF S et al. T-cell function and migration-two sides of the same coin[J]. NEJM, 2000, 343:1020- 1032 doi: 10.1056/NEJM200010053431407

[15]	ZITTAN E , STEINHART A H , MILGROM R et al. Su1778-The Toronto IBD global endoscopic reporting (TIGER) score:a single, easy to use endoscopic score for all IBD patients[J]. Gastroenterology, 2019, 156 (6): Supplement 1:S- 608

[16]	LAMB C A , O'BYRNE S , KEIR M E et al. Gut-selective integrin-targeted therapies for inflammatory bowel disease[J]. J Crohns Colitis, 2018, 12 (suppl_2): S653- S668 doi: 10.1093/ecco-jcc/jjy060

[17]	FEAGAN B G , RUTGEERTS P , SANDS B E et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369 (8): 699- 710 doi: 10.1056/NEJMoa1215734

[18]	SANDBORN W J , FEAGAN B G , RUTGEERTS P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2013, 369 (8): 711- 721 doi: 10.1056/NEJMoa1215739

[19]	SANDS B E , FEAGAN B G , RUTGEERTS P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed[J]. Gastroenterology, 2014, 147 (3): 618- 627 doi: 10.1053/j.gastro.2014.05.008

[20]	VERMEIRE S , LOFTUS E V JR , COLOMBEL J F et al. Long-term efficacy of vedolizumab for Crohn's disease[J]. J Crohns Colitis, 2017, 11 (4): 412- 424

[21]	UZZAN M , TOKUYAMA M , ROSENSTEIN A et al. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals[J]. Science Translational Medicine, 2018,

[22]	SANDBORN W J , FEAGAN B G , WOLF D C et al. Ozanimod induction and maintenance treatment for ulcerative colitis[J]. N Engl J Med, 2016, 374 (18): 1754- 1762 doi: 10.1056/NEJMoa1513248

[23]	FEAGAN B G , PANéS J , FERRANTE M et al. Risankizumab in patients with moderate to severe Crohn's disease:an open-label extension study[J]. Lancet Gastroenterol Hepatol, 2018, 3 (10): 671- 680 doi: 10.1016/S2468-1253(18)30233-4

[24]	PAPP K , GOTTLIEB A B , NALDI L et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)[J]. J Drugs Dermatol, 2015, 14 (7): 706- 714

[25]	WILS P , BOUHNIK Y , MICHETTI P et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients:a multicentre experience[J]. Aliment Pharmacol Ther, 2018, 47 (5): 588- 595 doi: 10.1111/apt.14487

[26]	SANDBORN W J , SU C , SANDS B E et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2017, 376:1723- 1736 doi: 10.1056/NEJMoa1606910

[27]	SANDBORN W J , PANNéS J , D'HAENS G R et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials[J]. Clin Gastroenterol Hepatol, 2019, 17 (8): 1541- 1550 doi: 10.1016/j.cgh.2018.11.035

[28]	LóPEZ-GARCíA A , ROVIRA M , JAUREGUI-AMEZAGA A et al. Autologous haematopoietic stem cell transplantation for refractory Crohn's disease:efficacy in a single-centre cohort[J]. J Crohns Colitis, 2017, 11 (10): 1161- 1168 doi: 10.1093/ecco-jcc/jjx054

[29]	PANéS J , GARCíA-OLMO D , VAN ASSCHEG et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease:a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388 (10051): 1281- 1290 doi: 10.1016/S0140-6736(16)31203-X

[1]	HU Yue, LYU Bin. Development and prospects of fecal microbiota transplantation[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 342-346.

[2]	LU Zhanjun,HU Yangyang,LI Sisi,ZANG Lijuan,JIANG Weiliang,WU Jianjiong,WU Xiening,ZENG Yue,WANG Xingpeng. Anti-inflammatory effect of interleukin-35 in mice with colitis and its mechanism[J]. J Zhejiang Univ (Med Sci), 2018, 47(5): 499-506.

[3]	QI Xiaohua,WANG Xinyi,HE Fan,LIU Biyao,ZHANG Tao,LI Fudong,ZHAI Yujia,LIN Junfen. Risk assessment for emergency events of infectious disease in outlying areas of large-scale activities[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 124-130.

[4]	ZHENG Qi,LU Meiping. Focus on pediatric rheumatic and immune diseases[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 213-217.

[5]	LU Shen,WANG Qingqing. Focus on the 14th International Symposium on Dendritic Cells[J]. J Zhejiang Univ (Med Sci), 2017, 46(1): 106-109.

[6]	Wei Jie-ping, Huang He. Highlights of the 19th Congress of Asia-Pacific Blood and Marrow Transplantation[J]. J Zhejiang Univ (Med Sci), 2015, 44(1): 112-115.

[7]	CHEN Xin-hua, ZHANG Xue-ming, YIN Sheng-yong, ZHENG Shu-sen. Bioelectric-technology in tumor minimally invasive therapy——from the 11th International Bioelectrics Symposium[J]. J Zhejiang Univ (Med Sci), 2015, 44(1): 108-111.

[8]	WANG Kan, et al. Highlights from 1st AGA professional conference in China[J]. J Zhejiang Univ (Med Sci), 2014, 43(6): 728-730.

Viewed

Full text

Abstract

Cited

Shared

Discussed